EUVIMED · CrossrefZeitschrift
The Lancet Haematology
ISSN 2352-3026 · Elsevier BV
Neueste Artikel
Rethinking the possibilities of adult ring sideroblastic anaemia
The expanding therapeutic landscape of β-thalassaemia
Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia
Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration
α-thalassaemia: an overlooked disease entering a new era
Bridging the thalassaemia divide in south and southeast Asia
MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study
Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial
Phenotype, treatment, and determinants of prognosis in Erdheim–Chester disease: an international, retrospective, cohort study
Rethinking anti-BCMA T-cell engager design
Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial
Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial
Improved survival after allo-HCT in Hodgkin lymphoma: true progress or time-dependent confounding?
Should plasma cell leukaemia be classified as multiple myeloma?
Improved survival after allo-HCT in Hodgkin lymphoma: true progress or time-dependent confounding? – Authors’ reply
Thalassaemia revisited: whose progress?
Hydroxyurea benefits for sickle cell anaemia in sub-Saharan Africa
From pain to purpose: my thalassaemia journey
From survival to self-determination: the chronic warrior
When inflammation conceals malignancy in the urinary bladder
Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies
Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers
Beyond maximum grade: key regulatory considerations in adverse event reporting
Beyond maximum grade: making toxicity count
Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial
Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group
Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party
Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial
EUVIMED